Apixaban Patent Expiration
Apixaban is Used for reducing the risk of stroke and systemic embolism. It was first introduced by Bristol Myers Squibb Co Pharmaceutical Research Institute
Apixaban Patents
Given below is the list of patents protecting Apixaban, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Eliquis Sprinkle |
US11896586 (Pediatric) | Apixaban formulations | May 22, 2041 | Bristol |
| Eliquis Sprinkle | US11896586 | Apixaban formulations | Nov 22, 2040 | Bristol |
| Eliquis |
US9326945 (Pediatric) | Apixaban formulations | Aug 24, 2031 | Bristol Myers Squibb |
| Eliquis | US9326945 | Apixaban formulations | Feb 24, 2031 | Bristol Myers Squibb |
| Eliquis |
US6967208 (Pediatric) | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | May 21, 2027 | Bristol Myers Squibb |
| Eliquis Sprinkle |
US6967208 (Pediatric) | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | May 21, 2027 | Bristol |
| Eliquis | US6967208 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | Nov 21, 2026 | Bristol Myers Squibb |
| Eliquis Sprinkle | US6967208 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | Nov 21, 2026 | Bristol |
| Eliquis | US6413980 | Nitrogen containing heterobicycles as factor Xa inhibitors |
Dec 22, 2019
(Expired) | Bristol Myers Squibb |
Apixaban's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Apixaban:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
